Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

Axe Cap view

Slowing Growth in Surgical Robotics: Watch Intuitive Surgical Carefully

Intuitive Surgical’s run has cooled, but its revenue base still looks steady amid rising competition.

Intuitive Surgical’s 40% drop from recent highs hasn’t been kind to shareholders, largely due to slowing sales of its flagship da Vinci surgical robots. With big players like Medtronic and Johnson & Johnson ramping up competition, growth fears are understandable. But what makes Intuitive Surgical interesting is its recurring revenue model—three-quarters of its sales come from parts and services, much like a subscription — which cushions the business from sudden shocks. Valuations are now below their five-year average, which suggests some market skepticism might be overdone. If AI developments begin to streamline robotic surgery further, this could be a catalyst for renewed growth. Still, investors should be wary: if competition erodes pricing power or slows adoption more than expected, the story will falter. For South African investors, this points to watching USD/ZAR carefully, as offshore tech stories remain sensitive to currency moves and dollar strength. this is just our opinion and not financial advice